BrainStorm Cell Therapeutics reported a net loss of $7.7 million for the nine months ended September 30, 2026, compared to $7.9 million in the prior year period. The company faces a significant stockholders' deficit of $12.3 million and maintains a very low cash position of $163 thousand, relying on private placements and short-term loans to fund operations.
BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.
Term
Q3 2026
“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”
Chaim Lebovits, President and Chief Executive Officer